Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects | Physiology
RNAi Inclisiran A Novel Approach to PCSK 9
Inclisiran (siRNA) for the Treatment of Hypercholesterolemia: PDUFA Date Set as December 2020
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
A) Simplified overview of mechanism of action by Inclisiran.... | Download Scientific Diagram
Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug's Approval | tctmd.com
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol | NEJM
Is Novartis' RNA Therapeutic Inclisiran Poised to Displace PCSK9 Antibodies and Become the Next Blockbuster Lipid-Lowering Drug?, Brent Osborne, Mike Rice
The Medicines Company: Limited Upside And A Tough Market Battle For Inclisiran (NASDAQ:MDCO) | Seeking Alpha
Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
Inclisiran—New hope in the management of lipid disorders? - Journal of Clinical Lipidology
The Medicines Company: Limited Upside And A Tough Market Battle For Inclisiran (NASDAQ:MDCO) | Seeking Alpha
ORION-4 — Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
ESC 2019 – Medicines Company impresses with inclisiran | Evaluate
References in Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies - Mayo Clinic Proceedings
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis | Journal of the American College of Cardiology
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
ORION-1 Inclisiran inhibits PCSK9 synthesis by RNA interference Planned interim analysis of a multi-center randomized controlled dose-finding trial Kausik. - ppt download
